Scott T. Tagawa, MD | Authors


Benefits and Limitations of Radium-223 in mCRPC

February 18, 2019

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian–Weill Cornell Medical Center, discusses benefits and limitations of radium-223 in metastatic castration-resistant prostate cancer.

Evaluating Tumor-Directed PET Imaging of mCRPC Bone Metastases Using Zr-89-J591

February 07, 2014

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.